Deciding if and when to pursue deep brain stimulation (DBS) can be overwhelming for people with Parkinson's disease. While ...

Deciding if and when to pursue deep brain stimulation (DBS) can be overwhelming for people with Parkinson's disease. While ...

For an estimated 11% of Americans over age 65 who have dementia and the over 11 million unpaid caregivers supporting them, ...

Jack Spencer is a senior research fellow for Energy and Environmental Policy at The Heritage Foundation. The Trump administration’s decision to rescind the endangerment finding regarding carbon ...

The researchers produced a report that was central in a Trump administration effort to stop regulating climate pollution. By Lisa Friedman Reporting from Washington A federal judge on Friday ruled the ...

Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. We’re all guilty of putting off that big decision because our ...

Eric Boodman focuses on narrative features, exploring the startling ways that science and medicine affect people’s lives. You can reach Eric on Signal at eboodman.88. But to researchers who’ve spent ...

STEM workforce shortages are a well-known global issue. With demand set to rise by nearly 11 percent in the next decade, today’s students are the solution. They will be the ones to make the next big ...

Run a small business and you probably feel like you make dozens of decisions every day. Whether to cut a quality corner, or miss a ship date. Whether to respond to a customer complaint, or hope the ...

OSLO, Dec 10 (Reuters) - Norway's central bank does not currently recommend the introduction of a central bank digital currency (CBDC), but may do so at a later time, it said on Wednesday. Norges Bank ...

Do you tend to take longer than other people to make a decision? Let’s find out. In a study published in Personality and Individual Differences, researchers asked participants to rate themselves in ...

Anavex Life Sciences faces a negative CHMP opinion on Anavex 2-73 for Alzheimer's, with re-examination unlikely to improve approval odds. AVXL's Phase 2B/3 trial failed to achieve statistical ...